Public Sector Pension Investment Board decreased its position in shares of AstraZeneca Plc (NYSE:AZN – Free Report) by 13.7% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,721,652 shares of the company’s stock after selling 272,726 shares during the period. AstraZeneca makes up about 0.6% of Public Sector Pension Investment Board’s investment portfolio, making the stock its 27th largest position. Public Sector Pension Investment Board owned 0.11% of AstraZeneca worth $271,673,000 at the end of the most recent reporting period.
A number of other hedge funds have also bought and sold shares of AZN. Professional Advisory Services Inc. purchased a new stake in AstraZeneca in the 2nd quarter worth about $30,241,000. Wealthcare Advisory Partners LLC purchased a new position in shares of AstraZeneca during the second quarter valued at approximately $2,296,000. Andra AP fonden boosted its position in shares of AstraZeneca by 122.9% during the second quarter. Andra AP fonden now owns 526,714 shares of the company’s stock valued at $99,876,000 after buying an additional 290,412 shares during the period. International Assets Investment Management LLC boosted its position in shares of AstraZeneca by 1,564.8% during the third quarter. International Assets Investment Management LLC now owns 28,785 shares of the company’s stock valued at $4,648,000 after buying an additional 27,056 shares during the period. Finally, Westport Asset Management Inc. bought a new position in shares of AstraZeneca during the second quarter valued at approximately $1,422,000. Institutional investors own 20.35% of the company’s stock.
AstraZeneca Price Performance
Shares of AZN stock opened at $182.23 on Wednesday. AstraZeneca Plc has a twelve month low of $153.41 and a twelve month high of $212.71. The company has a current ratio of 1.01, a quick ratio of 0.79 and a debt-to-equity ratio of 0.51. The stock has a fifty day simple moving average of $169.69 and a two-hundred day simple moving average of $180.18. The stock has a market capitalization of $282.62 billion, a price-to-earnings ratio of 25.77, a P/E/G ratio of 1.43 and a beta of 0.24.
AstraZeneca (NYSE:AZN – Get Free Report) last released its quarterly earnings data on Saturday, October 31st. The company reported $2.79 earnings per share for the quarter, topping analysts’ consensus estimates of $2.60 by $0.19. The company had revenue of $16.21 billion during the quarter, compared to analyst estimates of $16 billion. AstraZeneca had a net margin of 17.68% and a return on equity of 31.85%. The firm’s revenue for the quarter was up 6.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.38 earnings per share. On average, analysts predict that AstraZeneca Plc will post 10.22 EPS for the current fiscal year.
Key Stories Impacting AstraZeneca
These are some of the AZN stories that stood out recently:
- Positive Sentiment: The U.S. and EU approved Klygefa for generalized myasthenia gravis. Its once-weekly dosing may offer patients greater convenience and gives AstraZeneca another commercial opportunity. AstraZeneca Secures US, EU Nod for New Myasthenia Gravis Drug Klygefa
- Positive Sentiment: AstraZeneca fended off a lawsuit alleging it monopolized the market for Soliris, reducing a legal overhang. Separately, Baxfendy was recommended for EU approval after Phase III hypertension trials, a further pipeline milestone. AstraZeneca fends off lawsuit over alleged Soliris drug monopoly AstraZeneca’s Baxfendy Recommended for EU Approval
- Neutral Sentiment: AstraZeneca is cutting 600 U.S. sales jobs as a cost-saving program takes effect. Lower expenses could help margins, though the restructuring may bring operational changes. AstraZeneca Cuts 600 U.S. Sales Jobs
Wall Street Analyst Weigh In
AZN has been the subject of a number of research analyst reports. Wall Street Zen raised AstraZeneca from a “hold” rating to a “buy” rating in a research note on Saturday, October 31st. Weiss Ratings upgraded AstraZeneca from a “hold (c+)” rating to a “buy (b-)” rating in a report on Monday, October 26th. Nordea Equity Research raised AstraZeneca from a “sell” rating to a “buy” rating in a research report on Tuesday, October 13th. CICC Research assumed coverage on AstraZeneca in a research note on Sunday, August 23rd. They issued an “outperform” rating and a $198.00 target price on the stock. Finally, Deutsche Bank upgraded AstraZeneca from a “sell” rating to a “hold” rating in a research note on Tuesday, September 15th. Sixteen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $206.67.
View Our Latest Stock Analysis on AZN
AstraZeneca Profile
AstraZeneca plc is a global, science-led biopharmaceutical company headquartered in Cambridge, United Kingdom. The company discovers, develops and commercializes prescription medicines, with a focus on oncology, biopharmaceuticals and rare diseases. Its research and commercial operations serve patients and healthcare systems across more than 100 countries. AstraZeneca’s portfolio includes medicines for cancer, respiratory and immune-mediated conditions, cardiovascular, renal and metabolic diseases, and rare disorders.
Read More
- Five stocks we like better than AstraZeneca
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.
